Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024PRNewsWire • 11/05/24
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024PRNewsWire • 10/29/24
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 09/11/24
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePRNewsWire • 08/29/24
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsPRNewsWire • 07/29/24
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 06/04/24
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating RilvegostomigPRNewsWire • 05/30/24
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic PotentialPRNewsWire • 05/16/24